Motavizumab
From Wikipedia, the free encyclopedia
|
Motavizumab
|
|
|
|
|
| Source | Human |
| Target | ? |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | Approximately 148 kDa |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is currently being investigated by MedImmune for the prevention of respiratory syncytial virus infection in high-risk infants.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Alemtuzumab, Apolizumab, Aselizumab, Atlizumab, Bapineuzumab, Bevacizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Cedelizumab, Certolizumab pegol, Cidfusituzumab, Cidtuzumab, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Felvizumab, Fontolizumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab, Mepolizumab, Motavizumab, Motovizumab, Natalizumab, Nimotuzumab, Nolovizumab, Numavizumab, Ocrelizumab, Omalizumab, Palivizumab, Pascolizumab, Pecfusituzumab, Pectuzumab, Pertuzumab, Pexelizumab, Ralivizumab, Ranibizumab, Reslivizumab, Reslizumab, Resyvizumab, Rovelizumab, Ruplizumab, Sibrotuzumab, Siplizumab, Sontuzumab, Tacatuzumab tetraxetan, Tadocizumab, Talizumab, Tefibazumab, Tocilizumab, Toralizumab, Trastuzumab, Tucotuzumab celmoleukin, Tucusituzumab, Umavizumab, Urtoxazumab, Visilizumab
